دورية أكاديمية
Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.
| العنوان: | Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. |
|---|---|
| المؤلفون: | Gondi V; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD. vgondi@chicagocancer.org., Pugh SL; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Tome WA; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Caine C; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Corn B; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Kanner A; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Rowley H; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Kundapur V; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., DeNittis A; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Greenspoon JN; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Konski AA; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Bauman GS; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Shah S; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Shi W; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Wendland M; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Kachnic L; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD., Mehta MP; Vinai Gondi, Cadence Brain Tumor Center and CDH Proton Center, Warrenville, IL; Vinai Gondi and Howard Rowley, University of Wisconsin School of Medicine and Public Health, Madison, WI; Stephanie L. Pugh, Radiation Therapy Oncology Group Statistical Center; Wenyin Shi, Thomas Jefferson University Hospital, Philadelphia; Albert DeNittis, Lankenau Medical Center, Main Line Community Clinical Oncology Program (CCOP), Wynnewood; Andre A. Konski, Chester County Hospital, West Chester; Wolfgang A. Tome, Montefiore Medical Center and Albert Einstein College of Medicine, Yeshiva University, Bronx, NY; Chip Caine, Intermountain Medical Center and University of Phoenix, Salt Lake City, UT; Ben Corn and Andrew Kanner, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Jeffrey N. Greenspoon, McMaster University-Hamilton, Hamilton; Glenn S. Bauman, London Regional Cancer Program, London, Ontario, Canada; Sunjay Shah, Christiana Care Health Services CCOP, Newark, DE; Merideth Wendland, US Oncology-Willamette Valley Cancer Institute, Eugene, OR; Lisa Kachnic, Boston Medical Center Minority-Based CCOP, Boston, MA; and Minesh P. Mehta, University of Maryland School of Medicine, Baltimore, MD. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Dec 01; Vol. 32 (34), pp. 3810-6. Date of Electronic Publication: 2014 Oct 27. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | Radiotherapy, Intensity-Modulated*/adverse effects , Radiotherapy, Intensity-Modulated*/mortality, Brain Neoplasms/*radiotherapy , Brain Neoplasms/*secondary , Cranial Irradiation/*methods , Hippocampus/*radiation effects , Memory Disorders/*prevention & control , Mental Recall/*radiation effects , Neural Stem Cells/*radiation effects , Radiation Injuries/*prevention & control, Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/mortality ; Cognition ; Cranial Irradiation/adverse effects ; Cranial Irradiation/mortality ; Dose Fractionation, Radiation ; Female ; Hippocampus/physiopathology ; Humans ; Kaplan-Meier Estimate ; Male ; Memory Disorders/etiology ; Memory Disorders/mortality ; Memory Disorders/physiopathology ; Memory Disorders/psychology ; Middle Aged ; Neuropsychological Tests ; Quality of Life ; Radiation Injuries/etiology ; Radiation Injuries/mortality ; Radiation Injuries/physiopathology ; Radiation Injuries/psychology ; Risk Factors ; Surveys and Questionnaires ; Time Factors ; Treatment Outcome |
| مستخلص: | Purpose: Hippocampal neural stem-cell injury during whole-brain radiotherapy (WBRT) may play a role in memory decline. Intensity-modulated radiotherapy can be used to avoid conformally the hippocampal neural stem-cell compartment during WBRT (HA-WBRT). RTOG 0933 was a single-arm phase II study of HA-WBRT for brain metastases with prespecified comparison with a historical control of patients treated with WBRT without hippocampal avoidance. Patients and Methods: Eligible adult patients with brain metastases received HA-WBRT to 30 Gy in 10 fractions. Standardized cognitive function and quality-of-life (QOL) assessments were performed at baseline and 2, 4, and 6 months. The primary end point was the Hopkins Verbal Learning Test-Revised Delayed Recall (HVLT-R DR) at 4 months. The historical control demonstrated a 30% mean relative decline in HVLT-R DR from baseline to 4 months. To detect a mean relative decline ≤ 15% in HVLT-R DR after HA-WBRT, 51 analyzable patients were required to ensure 80% statistical power with α = 0.05. Results: Of 113 patients accrued from March 2011 through November 2012, 42 patients were analyzable at 4 months. Mean relative decline in HVLT-R DR from baseline to 4 months was 7.0% (95% CI, -4.7% to 18.7%), significantly lower in comparison with the historical control (P < .001). No decline in QOL scores was observed. Two grade 3 toxicities and no grade 4 to 5 toxicities were reported. Median survival was 6.8 months. Conclusion: Conformal avoidance of the hippocampus during WBRT is associated with preservation of memory and QOL as compared with historical series. (© 2014 by American Society of Clinical Oncology.) |
| التعليقات: | Comment in: J Clin Oncol. 2014 Dec 1;32(34):3789-91. (PMID: 25349293) Comment in: J Clin Oncol. 2015 Jun 10;33(17):1985. (PMID: 25897152) Comment in: J Clin Oncol. 2015 Jun 10;33(17):1986. (PMID: 25897163) Comment in: Strahlenther Onkol. 2015 Jun;191(6):534-5. (PMID: 26221646) |
| References: | Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1480-5. (PMID: 19625140) J Consult Clin Psychol. 1991 Feb;59(1):12-9. (PMID: 2002127) J Neurooncol. 2010 Jan;96(1):17-32. (PMID: 19960231) Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):826-34. (PMID: 18164853) Neuro Oncol. 2013 Oct;15(10):1429-37. (PMID: 23956241) Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1244-52. (PMID: 20598457) Radiother Oncol. 2010 Dec;97(3):370-6. (PMID: 20970214) Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):77-84. (PMID: 20800380) J Clin Oncol. 2013 Jan 1;31(1):65-72. (PMID: 23213105) Nat Med. 1998 Nov;4(11):1313-7. (PMID: 9809557) Cancer. 2013 Jan 1;119(1):226-32. (PMID: 22707281) Pract Radiat Oncol. 2012 Jul-Sep;2(3):210-225. (PMID: 25925626) Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):348-54. (PMID: 23312272) Nat Med. 2002 Sep;8(9):955-62. (PMID: 12161748) Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):64-70. (PMID: 18406884) Lancet Oncol. 2009 Nov;10(11):1037-44. (PMID: 19801201) J Clin Oncol. 2011 Jan 20;29(3):279-86. (PMID: 21135267) J Clin Oncol. 2003 Jul 1;21(13):2529-36. (PMID: 12829672) Radiother Oncol. 2010 Jun;95(3):327-31. (PMID: 20392503) Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):656-64. (PMID: 23597420) |
| معلومات مُعتمدة: | U10 CA180868 United States CA NCI NIH HHS; UG1 CA189867 United States CA NCI NIH HHS; U10 CA21661 United States CA NCI NIH HHS; U10 CA37422 United States CA NCI NIH HHS; UG1 CA189852 United States CA NCI NIH HHS; U10 CA037422 United States CA NCI NIH HHS; U10 CA021661 United States CA NCI NIH HHS; U10 CA180799 United States CA NCI NIH HHS; U10 CA180822 United States CA NCI NIH HHS |
| سلسلة جزيئية: | ClinicalTrials.gov NCT01227954 |
| تواريخ الأحداث: | Date Created: 20141029 Date Completed: 20150212 Latest Revision: 20220408 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC4239303 |
| DOI: | 10.1200/JCO.2014.57.2909 |
| PMID: | 25349290 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.2014.57.2909 |